
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
The authors describe a methodology to evaluate various gelatin raw materials with respect to their stability and resistance to cross­linking.
about 25 years ago
Fast-Melting Tablets: Developments and Technologiesabout 25 years ago
Compendium of Pharmaceutical Excipients for Vaginal Formulations




